Access
Email Verification
Draft Agenda 2024 coming soon...
If you would like to be a speaker at this event, please contact sean.collins@iQ-Hub.com, subject heading “Call for Papers - Drug Delivery Summit 2024”.
Agenda 2023
DAY 1: MONDAY, FEBRUARY 27, 2023
0830 - 0930 REGISTRATION AND MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1010 CHALLENGES OF IMPLEMENTING CSTDs IN NOVEL MODALITIES
- Understanding the pain points for novel modalities and highly potent biotherapeutics
- Considerations for Drug Product design, formulation, manufacturing, and compatibility in-use studies
- Case studies to be included for early-stage trials in the US and considerations for global expansion
Cesar Calero
Sanofi
Sanofi
1010 - 1040 EXPLOITING THE NOSE-TO-BRAIN PATHWAY TO BYPASS THE BLOOD-BRAIN-BARRIER FOR CNS DISEASE MANAGEMENT
- Exploring olfactory and trigeminal nerve pathways to transport drugs directly to the brain from the nose
- Enabling the delivery of a wider range of molecules at a much higher efficiency
- Optimised device development in combination with specific formulation strategies
Gemma Budd
Nanopharm Ltd
Nanopharm Ltd
1040 - 1100 MORNING COFFEE BREAK IN THE EXHIBIT AREASPONSORED BY SOLVIAS AG
1100 - 1130 NASAL DRUG DELIVERY: OPPORTUNITIES AND CHALLENGES
- Advantages and challenges of Nasal Drug Delivery
- Regulatory aspects and addressing the challenges
- Explore new innovations in Nose to Brain Delivery
Stuart Madden
Neurelis, Inc.
Neurelis, Inc.
1130 - 1200 DERISKING THE TRANSITION FROM VIAL TO DRUG-DEVICE COMBINATION PRODUCT
- Understanding regulatory guidance that impacts drug product submissions
- Strategies to mitigate risk in the combination product development
- Collection and evaluation of data needed to assess device reliability and robustness
Mike Ulman
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc.
1200 - 1330 NETWORKING LUNCH & VISIT THE DRUG DELIVERY SUMMIT EXHIBITION
1330 - 1400 ENGINEERED MICROBES FOR MUCOSAL DRUG DELIVERY
- Learn about FDA GRAS microbes that can be safely deployed into every mucosal tissue
- Tenza engineers microbes as vectors for mucosal delivery of biologics
- Enabling modalities for safer and more effective therapies
Anik Debnath
Tenza, Inc.
Tenza, Inc.
1400 - 1430 HOW TO SELECT (OR DESIGN) THE DELIVERY TECHNOLOGY THAT IS RIGHT FOR THE DRUG
- Identifying the right delivery technology for a particular drug delivery application
- EARLY identify the technological performance characteristics
Fubin Wu
GessNet
GessNet
1430 - 1500 AFTERNOON COFFEE BREAK IN THE EXHIBIT AREASPONSORED BY QUOTIENT SCIENCES
1500 - 1530 OVERCOMING COMPLEX FORMULATION CHALLENGES FOR SMALL MOLECULES & PEPTIDES
- Evaluating multiple formulation technologies for poorly soluble molecules
- Integrated manufacturing and clinical programs can expedite patient delivery
- Design space concepts in optimizing modified release formulation in “real-time” using clinical data
Aruna Railkar
Quotient Sciences
Quotient Sciences
1530 - 1600 NEW EXCIPIENT TO FORMULATE POORLY SOLUBLE APIs
- Introducing a new tool to formulate poor water-soluble APIs
- Case studies on the formulation of Aprepitant and Tacrolimus
- Facilitating formulation of long-acting injectables without the need for implants
Raj Arunagiri
Eastman Chemical Company
Eastman Chemical Company
1600 - 1630 EXPANDED IN-VITRO SIMULATION OF HANDLING ERROR TO IMPROVE INHALED THERAPY OUTCOME
- Learn accurate assessment of critical handling error
- Understand in-vitro simulation of device handling error
- Facilitation of effective patient training
Yannick Baschung
SOLVIAS AG
SOLVIAS AG
1630 - 1730 NETWORKING DRINKS RECEPTION
DAY 2: TUESDAY, FEBRUARY 28, 2023
0900 - 0930 MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1010 TRANSPARENT AI/ML TO DISCOVER NOVEL THERAPEUTICS FOR RNA SPLICING-MEDIATED DISEASES
- Convergence of innovative technologies to allow the use of AI/ML for the discovery of early R&D
- Leveraging Envisagenics’ SpliceCore platform to identify RNA splicing events for drug development
- Limitations of AI/ML and how to best approach a successful translation into downstream R&D stages
Kendall Anderson
Envisagenics
Envisagenics
1010 - 1040 USING SELF-EMULSIFYING DRUG DELIVERY SYSTEMS IN DRUG DEVELOPMENT
- Understand SEDDS as a great formulation tool for poorly soluble compounds
- Learn processes and options within SEDDS developments
- Evaluating drug design by using capsules within SEDDS formulations
Justin Kalafat
ACG NORTH AMERICA, LLC.
ACG NORTH AMERICA, LLC.
1040 - 1110 ISSUES IN DELIVERING HIGH-VOLUME, HIGH-VISCOSITY INJECTIONS
- Understand the factors contributing to volume/ viscosity increase
- Know more about human factor issues resulting from the delivery of high volumes/high viscosities
- Strategies to compensate for these issues
Michael Roe
kaléo
kaléo
1110 - 1130 MORNING COFFEE BREAK IN THE EXHIBIT AREASPONSORED BY MUNIT SA
1130 - 1200 PLATFORM COMBINATION PRODUCT STRATEGIES FOR HUMAN FACTORS
- Know the current HF practices and challenges for new and legacy combination products
- Understand regulatory & risk management aspects of human factors for combination products
- Applying a platform approach to an HF program that can be used in multiple products
Shannon Hoste | Stephanie Canfield
Agilis Consulting Group, LLC
Agilis Consulting Group, LLC
1200 - 1230 EMERGING FORMULATION TECHNOLOGIES OF NUTRACEUTICALS AND CANNABINOIDS
- Emerging formulation technologies for addressing severe malabsorption
- Safety and efficacy considerations associated with compliance and long-term use
- Formulation for product dosage forms and site of application
Andreas Papas
Antares Health Products Inc
Antares Health Products Inc
1230 - 1300 ENHANCING DRUG DELIVERY EXPERIENCE WITH DIGITAL SOLUTIONS
- Introducing Aptar vision on Drug + Digital + Device systems and how it can improve drug delivery
- Learning real-life product developments aiming at enhancing the patient experience
- Understand key factors for commercial success
Adam Shain
Aptar Digital Health
Aptar Digital Health
1300 - 1315 FEEDBACK & RAFFLE DRAW
1315 - 1430 NETWORKING LUNCH
Key topics for 2024:
- Formulation design for poorly soluble compounds
Understand the most recent technological advancements to improve the dissolution and bioavailability of poorly soluble drugs. - New drug delivery technologies for better deliverability
The future of drug deliveries across the skin barrier to systemic circulation via Iontophoresis, electroporation, sonophoresis, magnetophoresis, dermal patches, nanocarriers, needled and needle-less shots. - Latest developments in controlled released technologies
Evaluate controlled release methods which enhance the safety, efficacy, reliability, and convenience of drug therapy by controlling the rate and duration of drug release to control drug actions. - Optimizing drug formulations for continuous manufacturing
Learn about new methods in continuous pharmaceutical manufacturing for the pharmaceutical industry, which offers the potential for cost-reduction, enhanced efficiency, and economic viability. - Overcoming the blood-brain barrier and re-engineering biologics
Looking at the structural elements and anatomical features of the blood–brain barrier, various in vivo, in situ blood–brain barrier models, and adopting molecular Trojan horse technologies. - Developing new drug modalities and biotherapeutics
Achieve a deeper understanding of biotherapeutics and novel drug modalities beyond traditional small molecules, including RNA-based approaches, targeted protein degradation, covalent inhibitors, next-generation peptides, and antibodies.
Sponsorship Opportunities
Join us as a sponsor for this IQ International conference! Reach your target audience, limit competitor influence at the conference and become a keynote speaker, while sharing your company's solutions for this industry.
- Get registration discounts
- Enhance your brand awareness
- Additional marketing opportunities